Literature DB >> 16282595

Altered gene expression profiles reveal similarities and differences between Parkinson disease and model systems.

Renee M Miller1, Howard J Federoff.   

Abstract

Parkinson disease (PD) targets dopaminergic neurons in the substantia nigra, resulting in motor disturbances such as resting tremor, bradykinesia, and rigidity. Pathogenic processes likely occur over several decades, in that an overwhelming percentage of neurons are already dead at the time of clinical diagnosis. For this reason, the usage of animal model systems to discover the early steps in the pathologic cascade is required. These include exposure to the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), which selectively kills dopamine neurons in the substantia nigra, and genetic models incorporating mutations in the alpha-synuclein gene that cause disease in human patients. Through the evaluation of these models at multiple time points, it is possible to discover novel gene expression changes that may underlie disease pathogenesis. Specifically, the authors hypothesize that animal models of PD and human PD brains share a gene expression profile that signifies certain aspects of pathogenesis and/or recovery-resistance. To test this and similar hypotheses, the authors and others have utilized new microarray technology that enables the sampling of thousands of genes' expression level in one assay. Because the technology is fairly new and results can vary depending on methods used, results must be evaluated with care. Multiple array and data-mining options can be used to make the most accurate inferences as to differentially expressed genes in each set of samples. The authors developed a fusion classifier approach whereby individual data-mining algorithms generate lists of significant genes. The lists are subsequently queried, and only genes unanimously called significant are retained for further validation. Although the authors' approach identified hundreds of differentially expressed genes in each of three PD systems, only a few were common between the human and animal substantia nigra. These were related to dopamine phenotype, synaptic function, and the mitochondrial metabolism, implicating the presynaptic terminal as a primary site of injury. The time course of the authors' experiments indicates that if the synaptic changes could be prevented, this may alleviate some cell death, in that these changes precede neuronal loss.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16282595     DOI: 10.1177/1073858405278330

Source DB:  PubMed          Journal:  Neuroscientist        ISSN: 1073-8584            Impact factor:   7.519


  13 in total

Review 1.  Strategies to unravel molecular codes essential for the development of meso-diencephalic dopaminergic neurons.

Authors:  F M J Jacobs; S M Smits; K J M Hornman; J P H Burbach; M P Smidt
Journal:  J Physiol       Date:  2006-06-29       Impact factor: 5.182

Review 2.  Microarrays in Parkinson's disease: a systematic approach.

Authors:  Renee M Miller; Howard J Federoff
Journal:  NeuroRx       Date:  2006-07

Review 3.  Current status and future directions of gene expression profiling in Parkinson's disease.

Authors:  James G Greene
Journal:  Neurobiol Dis       Date:  2010-11-05       Impact factor: 5.996

4.  Neuroprotective changes of striatal degeneration-related gene expression by acupuncture in an MPTP mouse model of Parkinsonism: microarray analysis.

Authors:  Yeong-Gon Choi; Sujung Yeo; Yeon-Mi Hong; Sabina Lim
Journal:  Cell Mol Neurobiol       Date:  2010-11-25       Impact factor: 5.046

Review 5.  Using 'omics' to define pathogenesis and biomarkers of Parkinson's disease.

Authors:  W Michael Caudle; Theo K Bammler; Yvonne Lin; Sheng Pan; Jing Zhang
Journal:  Expert Rev Neurother       Date:  2010-06       Impact factor: 4.618

Review 6.  Aging--RNA in development and disease.

Authors:  Mark R Cookson
Journal:  Wiley Interdiscip Rev RNA       Date:  2011-09-06       Impact factor: 9.957

7.  Molecular profiling of a 6-hydroxydopamine model of Parkinson's disease.

Authors:  Sang J Na; Anthony G DiLella; Edward V Lis; Keith Jones; David M Levine; David J Stone; J F Hess
Journal:  Neurochem Res       Date:  2010-02-19       Impact factor: 3.996

8.  Gene expression profiling of substantia nigra dopamine neurons: further insights into Parkinson's disease pathology.

Authors:  Filip Simunovic; Ming Yi; Yulei Wang; Laurel Macey; Lauren T Brown; Anna M Krichevsky; Susan L Andersen; Robert M Stephens; Francine M Benes; Kai C Sonntag
Journal:  Brain       Date:  2008-12-03       Impact factor: 13.501

9.  Molecular docking study of catecholamines and [4-(propan-2-yl) phenyl]carbamic acid with tyrosine hydroxylase.

Authors:  Zahida Parveen; Muhammad Sulaman Nawaz; Shazi Shakil; Nigel H Greig; Mohammad A Kamal
Journal:  CNS Neurol Disord Drug Targets       Date:  2012-06-01       Impact factor: 4.388

10.  A cross-study transcriptional analysis of Parkinson's disease.

Authors:  Greg T Sutherland; Nicholas A Matigian; Alistair M Chalk; Matthew J Anderson; Peter A Silburn; Alan Mackay-Sim; Christine A Wells; George D Mellick
Journal:  PLoS One       Date:  2009-03-23       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.